Search Result

Results for "

TNF inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (24) Adenosine Kinase (1) AIM2 (2) Akt (1) Apoptosis (3) Autophagy (3) Bacterial (3) Bcl-2 Family (1) c-Myc (1) Casein Kinase (7) CDK (1) Chloride Channel (2) COX (3) E1/E2/E3 Enzyme (1) ERK (4) Estrogen Receptor/ERR (1) Exosomes (2) Formyl Peptide Receptor (FPR) (2) FOXO (1) HIV (2) IFNAR (1) Interleukin Related (13) IRAK (5) JNK (1) MAP3K (1) Necroptosis (1) NF-κB (5) NO Synthase (4) Oxidative Phosphorylation (2) p38 MAPK (9) Phosphodiesterase (PDE) (3) Prostaglandin Receptor (1) Proteasome (2) Pyruvate Kinase (2) Raf (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) RIP kinase (3) Salt-inducible Kinase (SIK) (1) Sirtuin (1) SOD (1) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (20) Cardiovascular Disease (3) Endocrinology (2) Infection (3) Inflammation/Immunology (37) Metabolic Disease (3) Neurological Disease (2)

By Targets:

TNF Receptor (24)

Adenosine Kinase (1)

AIM2 (2)

Akt (1)

Apoptosis (3)

Autophagy (3)

Bacterial (3)

Bcl-2 Family (1)

c-Myc (1)

Casein Kinase (7)

CDK (1)

Chloride Channel (2)

COX (3)

E1/E2/E3 Enzyme (1)

ERK (4)

Estrogen Receptor/ERR (1)

Exosomes (2)

Formyl Peptide Receptor (FPR) (2)

FOXO (1)

HIV (2)

IFNAR (1)

Interleukin Related (13)

IRAK (5)

JNK (1)

MAP3K (1)

Necroptosis (1)

NF-κB (5)

NO Synthase (4)

Oxidative Phosphorylation (2)

p38 MAPK (9)

Phosphodiesterase (PDE) (3)

Prostaglandin Receptor (1)

Proteasome (2)

Pyruvate Kinase (2)

Raf (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (5)

RIP kinase (3)

Salt-inducible Kinase (SIK) (1)

Sirtuin (1)

SOD (1)

Toll-like Receptor (TLR) (3)

By Research Areas:

Cancer (20)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (3)

Inflammation/Immunology (37)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: TNF Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0822

Shikonin Maximum Cited Publications 66 Publications Verification C.I. 75535; Isoarnebin 4	Exosomes Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2	Cancer
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM . Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit *TNF-α* and NF-κB pathway . Shikonin decreases exosome secretion through the inhibition of glycolysis . Shikonin inhibits AIM2 inflammasome activation .

HY-147141

HS-276 2 Publications Verification	IRAK TNF Receptor Casein Kinase Interleukin Related	Inflammation/Immunology
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 reduces the expression of *TNF, IL-6, and IL-1β*. HS-276 can be used for rheumatoid arthritis (RA) research .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-122882

HOIPIN-8 4 Publications Verification	E1/E2/E3 Enzyme	Inflammation/Immunology
HOIPIN-8 is a potent inhibitor of linear ubiquitin chain assembly complex (LUBAC) with an IC₅₀ of 11 nM. HOIPIN-8 is a HOIPIN-1 derivative with enhanced the potency by 255-fold in the petit-LUBAC inhibition, and 10-fold and 4-fold in the LUBAC- and TNF-α-mediated NF-κB activation, respectively than HOIPIN-1. HOIPIN-1 is a promising tool to explore the cellular functions of LUBAC .

HY-P4744

LL-37 amide 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-N0569

Madecassic acid 2 Publications Verification	NO Synthase COX TNF Receptor Interleukin Related	Inflammation/Immunology
Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by iNOS, COX-2, *TNF-alpha, IL-1beta, and IL-6* inhibition via the downregulation of NF-κB activation in RAW 264.7 macrophage cells .

HY-N6246

Asperulosidic Acid	NF-κB ERK	Inflammation/Immunology Cancer
Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-N7056

4'-Hydroxychalcone 3 Publications Verification	Oxidative Phosphorylation Proteasome	Inflammation/Immunology Cancer
4'-Hydroxychalcone is a chalcone isolated from licorice root, with hepatoprotective activity. 4'-Hydroxychalcone inhibits TNFα-induced NF-κB activation via proteasome inhibition. 4'-Hydroxychalcone induces a rapid potassium release from mitochondrial vesicles and causes deterioration of respiratory control and oxidative phosphorylation of isolated rat liver mitochondria .

HY-14622

Necrostatin 2 10+ Cited Publications	RIP kinase	Cancer
Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with *TNF-α* is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

HY-108642

AMG-548	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548, an orally active and selective p38α inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-N0863

Methyl protodioscin NSC-698790; Smilax saponin B	Bcl-2 Family Apoptosis Akt c-Myc ERK p38 MAPK JNK FOXO	Cancer
Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, *TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting* proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis .

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .

HY-108642B

AMG-548 dihydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-W002199

6:2 Fluorotelomer alcohol 6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol	Bacterial Apoptosis ERK TNF Receptor	Infection Neurological Disease
6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders .

HY-175479

GLPG4970	Salt-inducible Kinase (SIK) TNF Receptor Interleukin Related	Inflammation/Immunology
GLPG4970 is a potent, selective and orally active salt-inducible kinase 2/3 (SIK2/SIK3) dual inhibitor with IC₅₀ values of 0.3 nM and 0.7 nM. GLPG4970 has weak inhibition of hERG channel with an IC₅₀ of 29 μM. GLPG4970 can decrease TNFα release and increase IL-10 release GLPG4970 can be used for the researches of inflammation and immunology, such as colitis .

HY-B1608

Chromium chloride		Cardiovascular Disease Metabolic Disease
Chromium chloride is a trivalent chromium compound and an essential trace mineral. Chromium chloride enhances insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle. Chromium chloride regulates glucose and lipid metabolism, inhibits *TNF-α* secretion and oxidative stress in monocytes treated with high glucose or H₂O₂, and reverses hydrogen peroxide-induced cell growth inhibition. Chromium chloride reduces coronary and aortic lipid deposition and serum cholesterol levels in hypercholesterolemic rabbits. Chromium chloride can be used in research related to diabetes and cardiac atherosclerosis .

HY-10320A

Doramapimod hydrochloride 50+ Cited Publications BIRB 796 hydrochloride	Autophagy Raf p38 MAPK	Inflammation/Immunology
Doramapimod hydrochloride (BIRB 796 hydrochloride) is an anti-inflammatory compound with biological activity through inhibition of p38 MAPK. Doramapimod hydrochloride can significantly inhibit the activities of TNF-α and IL-1β induced by LPS, LTA and PGN. Doramapimod hydrochloride showed a stronger inhibitory effect on inflammation induced by all three bacterial toxins, which was more significant compared with the effects of other compounds. Doramapimod hydrochloride can be used in the research of autoimmune diseases .

HY-P4744A

LL-37 amide TFA 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-155830

Morcamilast ME3183; PDE4-IN-14	Phosphodiesterase (PDE) Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC₅₀s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of *TNF-α, IL-12/23p40, IL-23, and IL-17A* in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-117082

UTL-5g GBL-5g	TNF Receptor	Inflammation/Immunology
UTL-5g (GBL-5g), an anti-inflammatory *TNF-α* inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors .

HY-N0569R

Madecassic acid (Standard) 2 Publications Verification	Reference Standards NO Synthase COX TNF Receptor Interleukin Related	Inflammation/Immunology
Madecassic acid (Standard) is the analytical standard of Madecassic acid. This product is intended for research and analytical applications. Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by iNOS, COX-2, *TNF-alpha, IL-1beta, and IL-6* inhibition via the downregulation of NF-κB activation in RAW 264.7 macrophage cells .

HY-N0822R

Shikonin (Standard) C.I. 75535 (Standard); Isoarnebin 4 (Standard)	Reference Standards Exosomes Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2	Cancer
Shikonin (Standard) is the analytical standard of Shikonin. This product is intended for research and analytical applications. Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM . Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway . Shikonin decreases exosome secretion through the inhibition of glycolysis . Shikonin inhibits AIM2 inflammasome activation .

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-178287

TNF-α-IN-27	TNF Receptor	Inflammation/Immunology
TNF-α-IN-27 (Compound 1) is a *TNF-α* inhibitor with inhibition rate of 64% at 10 μM. TNF-α-IN-27 can be used for the researches of inflammation and immunology, such as asthma .

HY-130073

Amorfrutin A	NF-κB Apoptosis	Cancer
Amorfrutin A is the inhibition of NF-κB activation, that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity. Amorfrutin A promotes TNF-α-induced apoptosis in HeLa cell through promotion of caspase-3 and PARP proteolysis .

HY-177305

Anti-inflammatory agent 105	TNF Receptor	Inflammation/Immunology
Anti-inflammatory agent 105 (Compound 12) is an anti-inflammatory compound. The IC₅₀ of Anti-inflammatory agent 105 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.124 nM .

HY-32015

Cot inhibitor-1 2 Publications Verification	MAP3K	Inflammation/Immunology
Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC₅₀ of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC₅₀ of 5.7 nM .

HY-177304

Anti-inflammatory agent 104	TNF Receptor	Inflammation/Immunology
Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. The IC₅₀ of Anti-inflammatory agent 104 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.024 nM. Anti-inflammatory agent 104 can reduce eosinophils in rat lungs by 63% .

HY-172430S

Epaldeudomide	TNF Receptor	Cancer
Epaldeudomide (Compound A406) is the inhibitor for *TNF-α* (>50% inhibition rate at 100 nM). Epaldeudomide inhibits the proliferation of cancer cells MM.1S (IC₅₀ < 300 nM), WSU-DLCL-2 (IC₅₀ < 100 nM) and Rec-1 (IC₅₀ < 100 nM). Epaldeudomide exhibits antineoplastic activity .

HY-18754A

FR 167653 FR 167653 sulfate	p38 MAPK Autophagy	Endocrinology
FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .

HY-161630

TLR8 agonist 8	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .

HY-163755

GPER activator 1	Estrogen Receptor/ERR	Inflammation/Immunology
GPER activator 1 (compound 6-26) is a GPER-selective compound without cytotoxicity. GPER activator 1 exhibits dual inhibition of TNFα- and IL-6-induced inflammation .

HY-N12653

Exserohilone (-)-Exserohilone	Reactive Oxygen Species (ROS)	Metabolic Disease
Exserohilone ((-)-Exserohilone) is a thiodiketopiperazine derivative that exhibits the inhibition of TNF-α-induced ROS generation and MMP-1 secretion. Exserohilone increases the procollagen type I α1 secretion in human dermal fibroblasts .

HY-153579

Anti-inflammatory agent 42	Interleukin Related	Inflammation/Immunology
Anti-inflammatory agent 42 (Compound 10j) is an anti-inflammatory agent. Anti-inflammatory agent 42 shows excellent inhibition on the expression of TNF-α and IL-6 in LPS (HY-D1056)-stimulated macrophages .

HY-147950

PDE4-IN-10	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-10 (compound 7a) is a potent PDE4 inhibitor, with an IC₅₀ of 7.01 μM for PDE4B. PDE4-IN-10 shows selectivity, microsomal stability, inhibition of *TNF-α* and no major toxicities in vitro .

HY-131340

LASSBio-1632	Phosphodiesterase (PDE)	Inflammation/Immunology
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion .

HY-162097

RIPK1-IN-20	RIP kinase Necroptosis	Cancer
RIPK1-IN-20 (compound 13c) has a favorable RIPK1 kinase inhibition activity with an IC₅₀ value of 59.8 nM. RIPK1-IN-20 blocks TNFα-induced necroptosis in both human and murine cells (EC₅₀=1.06–4.58 nM) .

HY-114981

SRTCX1002	Sirtuin	Inflammation/Immunology
SRTCX1002 is a potent activator of SIRT1 (STAC), suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB Activity. SRTCX1002 suppresses stimuli-induced NF-κB transcriptional activation and LPS-induced TNFα secretion with IC₅₀s of 0.71 and 7.58 µM, respectively .

HY-18754

FR 167653 free base	p38 MAPK Autophagy	Endocrinology
FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .

HY-N6246R

Asperulosidic Acid (Standard)	Reference Standards NF-κB ERK	Inflammation/Immunology Cancer
Asperulosidic Acid (Standard) is the analytical standard of Asperulosidic Acid. This product is intended for research and analytical applications. Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-161629

TLR8 agonist 7	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 7 (Compound II-36) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ <250 nM. TLR8 agonist 7 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 7 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 98% .

HY-161631

TLR8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 9 (Compound II-77) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 9 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 9 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 97% .

HY-162600

CDK8-IN-15	CDK	Inflammation/Immunology
CDK8-IN-15 (Compound 46) is a potent CDK8 inhibitors with an IC₅₀ value of 57 nM. It can enhance the thermal stability of CDK8 along with inhibition against NF-κB and have favourable selectivity across the CDK family and tyrosine kinase. Additionally, it also demostrates a positive effect in vitro psoriasis model induced by TNF-α and alleviats the inflammatory response enhancing the expression of Foxp3 and IL-10, which is promising for research of psoriasis diseases .

HY-108642A

AMG-548 hydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 hydrochloride, an orally active and selective p38α inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 hydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 hydrochloride inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-168935

Anti-inflammatory agent 95	NO Synthase TNF Receptor Interleukin Related	Inflammation/Immunology
Anti-inflammatory agent 95 (Compound 2e) is an anti-inflammatory agent that exhibits the most potent anti-inflammatory activity in LPS (HY-D1056)-induced RAW 264.7 mouse macrophages. It significantly inhibits the production of NO, with an IC₅₀ of 8.8 μM, and reduces the secretion of *TNF-α* and IL-1β, with inhibition rates reaching 60% and over 90%, respectively, at a concentration of 100 μM. Anti-inflammatory agent 95 holds promise for research in the field of inflammatory diseases .

HY-N9086A

(rac)-Poriol 5,7,4'-Trihydroxy-6-methylflavanone	NO Synthase COX Interleukin Related	Inflammation/Immunology
(rac)-Poriol (5,7,4'-Trihydroxy-6-methylflavanone) exhibits antioxidant activity, and scavenges free radical DPPH with an IC₅₀ of 0.18 µg/mL. (rac)-Poriol inhibits the LPS (HY-D1056)-induced NO generation in RAW264.7 (98.35% inhibition rate at 10 μM), and exhibits anti-inflammatory activity. (rac)-Poriol exhibits good binding affinity with iNOS, COX-1, COX-2, TNF-α, and IL-1β .

HY-171837A

t9,t11,c15-CLNA	TNF Receptor Interleukin Related SOD	Inflammation/Immunology
t9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. t9,t11,c15-CLNA has the main activities of anti-inflammatory, antioxidant and improving intestinal barrier function. The regulatory mechanism of t9,t11,c15-CLNA includes upregulation of tight junction proteins, inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6) and activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be used in the study of inflammatory bowel diseases (such as colitis) .

HY-177155

p38α-IN-10	p38 MAPK TNF Receptor	Cardiovascular Disease Inflammation/Immunology
P38α-IN-10 (Compound 8) is an orally active inhibitor of p38α, with an IC₅₀ of 230 nM. P38α-IN-10 has an inhibitory effect on TNF production induced by LPS (HY-D1056). P38α-IN-10 can be used for the study of diseases such as rheumatoid arthritis and septic shock .

HY-182503

GP515	Adenosine Kinase	Others Inflammation/Immunology
GP515 is a potent and selective adenosine kinase inhibitor with a human IC₅₀ of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of *TNF-α* production with an IC₅₀ of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .

Cat. No.	Product Name	Target	Research Area